Shamburg News · 8-K filed Nov 12, 2026, 4:24 PM EST

Armata Pharmaceuticals Reports Q3 2026 Net Income of $54.9 Million on Convertible Loan Fair Value Gain

ARMP · Armata Pharmaceuticals, Inc.

  • Earnings
  • Financial statements
  • Materiality: high

Armata Pharmaceuticals announced financial results for the third quarter ended September 30, 2026, in a press release furnished as Exhibit 99.1. The company reported grant and award revenue of $3.2 million and a net income of $54.9 million, or $1.15 per basic share and a ($0.24) loss per diluted share, driven by a $69.6 million gain from the change in fair value of its convertible loan. Operating loss was approximately $7.4 million, compared with approximately $7.8 million a year earlier.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001104659-26-126274.

Written from the filing by Shamburg Markets. Figures are as reported by the company.